glp-1 agonist dpp 4 inhibitor Role of Dipeptidyl Peptidase Inhibitors in Antidiabetic Treatment GLP-1 receptor agonist versus DPP-4

Notably, Illinois adopted legislation in 2024 that requires coverage of certain weight loss and obesity medications in the state employee health plan

This research topic will feature reviews on the structural biology, pharmacology and clinical development of GLP-1 (and related peptides) receptor agonists and multi-agonists also targeting other receptors, and of DPP-4 inhibitors

Funding Statement The authors declare that this study received philanthropic funding from Alan and Tatyana Forman through Altronix Inc

Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review

After doctors noticed mice and humans on the drug for diabetes appeared to lose weight, they began to consider its use in obesity science

Statements Author contributions FK: Writing original draft, Visualization